Rare Disease Diagnostics Market Report 2026

Rare Disease Diagnostics Market Overview

• Rare Disease Diagnostics market size has reached to $38.14 billion in 2025 • Expected to grow to $62.18 billion in 2030 at a compound annual growth rate (CAGR) of 10.4% • Growth Driver: A Surge In Rare Disease Incidence And Diagnostics • Market Trend: Technological Advancements Reshaping Diagnostics • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rare Disease Diagnostics Market?

Rare disease diagnostics refers to the process of identifying and diagnosing medical conditions that are considered rare or uncommon. These diagnostics are used for early detection and diagnosis, as well as the selection of targeted and personalized treatment plans for uncommon disorders. The main tests included in rare disease diagnostics are genetic tests, general lab tests, and imaging tests. A genetic test refers to a laboratory procedure that examines the chromosomes, genes, or gene expression in human cells or tissue. The various technologies are included, such as capillary sequencing, whole genome sequencing, whole exome sequencing, and microarrays that use different samples, such as deoxyribonucleic acid (DNA) samples, buccal swab samples, blood, and saliva, for various diseases diagnosis, including gastroenterology disease, endocrine and metabolism disorders disease, hematology and oncology disease, dermatology disease, cardiovascular disorders, and neurology disease. These are used by several end-users, such as hospital laboratories, diagnostics laboratories, genetic testing laboratories, and cancer research laboratories.

What Is The Rare Disease Diagnostics Market Growth Forecast?

The rare disease diagnostics market size is expected to see rapid growth in the next few years. It will grow to $62.18 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to expansion of personalized medicine adoption, rising investments in genomics research, growing demand for early-stage rare disease detection, increasing integration of ai-driven diagnostic tools, expansion of rare disease screening programs. Major trends in the forecast period include increasing adoption of next-generation sequencing diagnostics, rising use of multi-gene panel testing, growing integration of advanced imaging in rare disease diagnosis, expansion of centralized rare disease testing centers, enhanced focus on early and accurate diagnosis.

What Is The Driver Of The Rare Disease Diagnostics Market?

The increasing incidence of rare diseases is expected to propel the growth of the rare disease diagnostics market going forward. Rare diseases are health conditions that affect a small proportion of the population compared to more common diseases, often requiring specialized diagnostic tools for early and accurate detection. Rare disease diagnostics help improve disease management, enable identification of potential therapeutics, and reduce unnecessary or harmful treatments, thereby supporting more effective patient care. For instance, in March 2025, according to Kidney Research UK, an UK-based kidney disease charity, currently, the rare kidney disease landscape includes over 150 distinct conditions, affecting an estimated 70 per 100,000 people, predominantly arising from genetic alterations. Therefore, the surge in rare disease incidence is driving the growth of the rare disease diagnostics industry.

Key Players In The Global Rare Disease Diagnostics Market

Major companies operating in the rare disease diagnostics market are Thermo Fisher Scientific Inc., Roche Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Sanofi Genzyme, Illumina Inc., Bio Rad Laboratories Inc., Qiagen NV, OPKO Health Inc., Natera Inc., Invitae Corporation, BGI Genomics Co. Ltd., 23andMe Holding Co., Ambry Genetics Corporation, Centogene N.V., GENEWIZ Inc., Blueprint Genetics Inc., Oxford Gene Technology Limited, Strand Life Sciences Pvt. Ltd., RareCyte Inc., Sophia Genetics SA, Foundation Medicine Inc.

Global Rare Disease Diagnostics Market Trends and Insights

Major companies operating in the rare disease diagnostics market are focusing on developing advanced solutions, such as high-sensitivity whole genome sequencing (WGS) platforms, to improve diagnostic precision, expand variant detection, and accelerate the identification of complex rare disorders. High-sensitivity WGS platforms enable comprehensive analysis of nearly all disease-causing genetic variants in a single test, supporting earlier and more accurate diagnoses. For instance, in April 2023, Centogene GmbH, a Germany-based rare disease company, launched CentoGenome, an enhanced next-generation sequencing (NGS)-based whole genome sequencing solution designed for the diagnosis of rare and neurodegenerative diseases. The platform delivers broad variant coverage, including Copy Number Variations (CNVs) associated with spinal muscular atrophy (SMA) and complex pathogenic variants linked to Gaucher disease (GD) and GBA1-related Parkinson’s disease. Additionally, CentoGenome incorporates PCR-free technology to reduce sequencing bias in difficult genomic regions, enabling higher-quality data and deeper insight into coding, regulatory, and intronic areas to support more accurate clinical interpretation.

What Are Latest Mergers And Acquisitions In The Rare Disease Diagnostics Market?

In August 2024, Labcorp, a US-based diagnostics and laboratory services company, acquired select assets from Invitae for an undisclosed amount. Through this acquisition, Labcorp seeks to strengthen its position in the rare disease diagnostics market by integrating Invitae’s advanced genetic testing assets and expanding access to high-complexity genomic diagnostics for underserved patient groups. Invitae is a US-based genetic testing and diagnostics company specializing in rare disease testing.

What Defines the Rare Disease Diagnostics Market?

The rare disease diagnostics market consists of revenues earned by entities by providing services such as clinical evaluation, parallel sequencing, targeted sequencing, laboratory testing, and specialist consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare disease diagnostics market also includes sales of vision evaluation instruments, blood pressure cuffs, cardiac monitors, and advanced imaging equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rare Disease Diagnostics Market Report 2026?

The rare disease diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rare disease diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.